Marshall Wace’s Nephros NEPH Stock Holding History

Marshall Wace’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,983	Closed	-$107K	–	3532
2025 Q4	$107K	Buy	+21,983	New	+$112K	﹤0.01%	2707

Other funds holding NEPH

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cornerstone Capital Palo Alto, California $1B AUM 21.47% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Marshall Wace's NEPH Position: Q1 2026 in Review

Marshall Wace sold out of Nephros (NEPH) in Q1 2026, closing a stake of 21,983 shares — an estimated $107K sold.

Marshall Wace first reported a position in NEPH in Q4 2025 and held it in 1 quarter. The position peaked at $107K in Q4 2025. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

Marshall Wace reported no remaining Nephros position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 21,983 Nephros shares in Q1 2026, an estimated $107K.
Marshall Wace first reported a position in Nephros in Q4 2025 and held it in 1 quarter.
Marshall Wace's Nephros position peaked at $107K in Q4 2025.
27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.